‘Dancing Molecules’ Treatment Receives FDA Orphan Drug Designation - News Center

‘Dancing Molecules’ Treatment Receives FDA Orphan Drug Designation

A longitudinal spinal cord section treated with the most bioactive therapeutic scaffold. Regenerated axons (shown in red) regrew within the lesion. To administer the treatment, researchers inject the liquid therapy into the region where a spinal cord injury occurred. The liquid then gels into a network of nanofibers, which serve as a scaffold to support cell growth.

“Dancing molecules,” a promising new treatment for acute spinal cord injuries developed at Northwestern University, has received Orphan Drug Designation from the U.S. Food and Drug Administration.